Abacavir/dolutegravir/lamivudine (Triumeq) is a once-daily HIV medication recommended for adults and adolescents with HIV, but only for those who are HLA-B*5701 negative. HLA-B*5701 is a genetic mutation associated with abacavir (ABC, Ziagen) hypersensitivity.
The medication comes in tablet form, with each tablet containing: 600 mg abacavir (Ziagen), 50 mg dolutegravir (Tivicay, DTG) and 300 mg lamivudine (3TC, Epivir). The main component of the regimen is dolutegravir, which is part of the integrase inhibitors drug class and continues to show high potency, safety and limited drug interactions.
Abacavir/dolutegravir/lamivudine should be taken once a day, with or without food.
There can be serious, life-threatening side effects associated with abacavir/dolutegravir/lamivudine, including allergic reactions, lactic acidosis and severe liver problems.
See full prescribing information here for additional warnings and indications.